Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Nobody Wants To Foot The Bill For New Antibiotics: Norwegian Study -- Sciencedaily

The skinny on pigs and pork | New Hampshire

She says that the goal for new antibiotics is first and foremost to weaken bacteria rather than kill them completely. "Antibiotics do not need to kill the bacteria entirely. If we can strengthen a person's immune system, weakening the bacteria may be enough for pics of mrsa the immune system to clean up the rest. In the new project we're going to try new combinations of antibiotics. It may be that an antibiotic that has lost its effect will work if we combine it with others.
For the original version including any supplementary images or video, visit http://www.sciencedaily.com/releases/2015/05/150507081950.htm

Bio Protection Services Launches New Mobile-Friendly Website Design

In order to stay in the competition, websites must make the change, and now Bio Protection Services is ahead. The new site features a sleek and simple design which details the services Bio Protection Services provides, the markets that they serve, and the way in which their products and services stand out against the rest. Bio Protection Services new website, designed by Blue Fire Media Group, is mobile-friendly for all types of devices including tablets, cell phones, and internet TVs. The modern and simple design helps emphasize the companys dedication to stay on top of the leading technology and to provide its customers with the best service possible. Bio Protection Services works with its customers to develop a disinfection and/or purification and prevention plan specific to the goals that company is looking to achieve. An accordion style set-up on the FAQ page allows customers to learn more about how they can benefit from Bio Protection Services, and a short video clip lets users discover how Bio Protection Services protects against some of todays worst health threats.
For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/05/prweb12711199.htm

Estabrook outlines antibiotic use from a treatment for sick animals to a routine part of hog management that creates new problems, including a rise in drug-resistant super-bugs like MRSA. "An examination of pork chops and ground pork published by Consumer Reports in 2012 showed that two-thirds of samples tested positive" for bacteria that cause "potentially fatal" illness in people, he notes. In addition to food safety, Estabrook reveals the "nuisance" of large-scale pig farming, visiting homeowners who can't go outside because of the fumes from neighboring commercial farms. He watches manure lagoons overflow in a downpour, and visits Des Moines Water Works in Iowa, which struggles to keep municipal drinking water safe in a state where "we all live downwind of a factory hog farm," as one mother told Estabrook. But "Pig Tales" isn't a diatribe. Estabrook examines ill-treatment of animals, environmental degradation, and human costs of industrial farming, But he also respects those trying to make a living and points out alternatives.
For the original version including any supplementary images or video, visit http://www.unionleader.com/article/20150510/NEWHAMPSHIRE02/150519975&source=RSS

Tetraphase Pharmaceuticals Reports First-Quarter 2015 Financial Results - Yahoo Finance

The webcast will be recorded and available for replay on the Tetraphase website for 30 days following the call. About Eravacycline Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and http://mrsahelp.info/very-fast-mrsa-bacteria-natural-treatment-review-in-newfield/ oral antibiotic in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). This program includes two phase 3 clinical trials: IGNITE1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE2 for complicated urinary tract infections (cUTI). Eravacycline has been designated by the FDA as a Qualified Infectious Disease Product (QIDP) for both the cIAI and cUTI indications. This designation, which is assigned to qualifying new antibiotic product candidates, makes eravacycline eligible to benefit from certain development and commercialization incentives, including priority review, and eligibility for both fast-track status and an additional five years of U.S. market exclusivity. About Tetraphase Pharmaceuticals, Inc. Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/tetraphase-pharmaceuticals-reports-first-quarter-200100309.html

Don't be the product, buy the product!